文献速递角膜与眼表疾病

核黄素联合紫外线A角膜交联治疗进展性圆锥角膜:十五年结果

Corneal Crosslinking With Riboflavin and UVA Light in Progressive Keratoconus: Fifteen-Year Results.
PubMed 文献 · Am J Ophthalmol · 2023-02-01

该研究分析2001至2006年在德国德累斯顿大学医院接受核黄素联合紫外线A角膜交联治疗的进展性圆锥角膜患者,42眼完成15年随访。最大角膜曲率从术前61.6D降至术后55.1D(P<.001),平均角膜曲率从50.3D降至47.5D(P<0.001),最佳矫正远视力从0.4改善至0.2 logMAR,14%需再次治疗,36%出现浅层角膜基质轻度瘢痕。结论认为角膜交联是进展期圆锥角膜的有效治疗方法,可实现长期稳定且无严重并发症。

要点

  • 15年随访显示最大角膜曲率从61.6D显著降至55.1D(P<.001)。
  • 最佳矫正远视力从0.4显著改善至0.2 logMAR。
  • 14%患眼需再次治疗,36%出现浅层角膜基质轻度瘢痕。

核心结论

  • 角膜交联被证明是治疗进展期圆锥角膜的有效方法,实现长期稳定且无严重并发症或副作用。

研究设计与样本

  • 回顾性随访分析干预性研究患者,纳入2001至2006年在德国德累斯顿卡尔·古斯塔夫·卡鲁斯大学医院眼科接受治疗的进展性圆锥角膜眼,按标准方案行核黄素联合紫外线A角膜交联,共42眼完成15年完整随访。

主要发现

  • 患者基线平均年龄26.9岁(95%CI:25.0-28.8)。
  • 最大角膜曲率术前61.6D(95%CI:58.2-64.9)降至术后55.1D(95%CI:51.6-58.4),下降有统计学显著意义(P<.001)。
  • 平均角膜曲率从50.3D(95%CI:48.3-52.4)降至47.5D(95%CI:45.3-49.4)(P<0.001)。
  • 最薄角膜厚度统计学显著减少40µm(95%CI:24-56)(P<.001)。
  • 最佳矫正远视力从0.4 logMAR统计学显著改善至0.2 logMAR。

关键数值与推荐

  • 14%的病例需要再次治疗。
  • 36%的患眼观察到浅层角膜基质轻度瘢痕,其中67%视力稳定或甚至改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the 15-year results of corneal crosslinking (CXL) in progressive keratoconus. DESIGN: Retrospective follow-up analysis of interventional study patients. METHODS: This study included keratoconic eyes with progressive disease treated from 2001 to 2006 at the Department of Ophthalmology, Carl Gustav Carus University Hospital, TU Dresden, Germany. CXL was performed by applying riboflavin and ultraviolet A (UVA) light according to a standard protocol. The best-corrected distance visual acuity (BCVA), slitlamp examination, and corneal topography as well as corneal thickness values were recorded preoperatively and 15 years after the treatment. RESULTS: A total of 42 eyes received a complete follow-up of 15 years. The mean age of the patients at baseline was 26.9 (95% CI: 25.0-28.8) years. The maximum keratometry was 61.6 (95% CI: 58.2 - 64.9) diopters (D) preoperatively and 55.1 (95% CI: 51.6-58.4) D postoperatively; the decrease was statistically significant (P < .001). The mean keratometry value changed from 50.3 (95% CI: 48.3-52.4) D to 47.5 (95% CI: 45.3-49.4) D (P < 0.001). Furthermore, the thinnest corneal thickness decreased statistically significantly by 40 (95% CI: 24-56) µm (P < .001). The BCVA improved statistically significantly from 0.4 to 0.2 logMAR after the treatment. Retreatment was needed in 14% of cases. Mild scarring of the superficial stromal corneal layers was observed in 36% of the eyes, and in 67% of them visual acuity was stable or even improved. CONCLUSIONS: The CXL procedure proved to be an effective method in the treatment of keratoconic eyes in the progressive stage of the disease, and achieved long-term stabilization without the occurrence of serious complications or side effects.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Raiskup F, Herber R, Lenk J, et al. Corneal Crosslinking With Riboflavin and UVA Light in Progressive Keratoconus: Fifteen-Year Results. Am J Ophthalmol. 2023. PMID: 36736417. doi:10.1016/j.ajo.2023.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。